Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biohaven

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Investors Business Daily

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.

Investors Business Daily

Pfizer To Pay Million In Kickback Scheme Settlement

Pfizer settles million over kickbacks for Nurtec ODT prescriptions; whistleblower rewarded.

Top News

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

Biohaven Getting Closer To Key Technical Benchmark

Biohaven shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.

Benzinga

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study.

Investors Business Daily

Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease

Biohaven stock jumped Monday after the company's experimental drug slowed progression in a rare disease with no approved treatments.

Investors Business Daily

New Migraine Drugs No Better Than Cheap Painkillers: Big Study

Migraine drugs can represent big money for pharmaceutical firms, as shown when Pfizer acquired Biohaven -- which developed rimegepant -- for more than $10 billion in 2022.

Latin Times

Biohaven Stock Earns Relative Strength Rating Upgrade

Biohaven sees its Relative Strength Rating move into the elite 90-plus level.

Investors Business Daily

Biohaven Reaches 80-Plus Relative Strength Rating Benchmark

A Relative Strength Rating upgrade for Biohaven shows improving technical performance.

Investors Business Daily

Stocks Generating Improved Relative Strength: Biohaven

A Relative Strength Rating upgrade for Biohaven shows improving technical performance. Will it continue?

Investors Business Daily

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Investors Business Daily

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review

A stock market rally attempt started midweek, but it's not a confirmed uptrend yet. Nike, Costco, Amazon and Meta were newsmakers.

Investors Business Daily

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.

Investors Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Tribune News Service

Pfizer’s COVID cash powers a ‘marketing machine’ on the hunt for new supernovas

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions.

Fortune

Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortune

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Investors Business Daily

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test

Biohaven Pharmaceutical said Thursday its experimental ALS treatment failed in a midstage study, leading BHVN stock to dip slightly.

Bangkok Post

Tisco Bank unit touts healthcare, biotech

Tisco Bank's wealth advisory unit suggests moving away from energy stocks to biotechnology and healthcare as several US economic indicators have signalled a higher risk of recession.

Benzinga

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations